NEWS

2015/11/10MEDICAL UPDATE

New study provides insights into potential treatment of severe pain in Parkinson’s disease with prolonged-release oxycodone/naloxone

Dublin, 10 November 2015 - A study published in The Lancet Neurology has provided important insights into the analgesic effects of prolonged release oxycodone/naloxone (OXN PR) for Parkinson’s disease patients with chronic, severe pain.[1]   The primary endpoint of improved average 24-hour pain score with OXN PR versus placebo at week 16 was not met (p=0.058), however assessments at other time points as well as secondary endpoint data indicate some potentially positive treatment effects with OXN PR.[1]

READ MORE

2015/02/25MEDICAL UPDATE

Oral OTEZLA® (apremilast) Approved in the EU for the Treatment of Plaque Psoriasis and Psoriatic Arthritis

Plaque Psoriasis:   OTEZLA® is indicated for the treatment of moderate-to-severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA). _____________________________________________________________________   Psoriatic Arthritis:   OTEZLA®  is indicated alone or in combination with Disease Modifying Antirheumatic Drugs (DMARDs), for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.

READ MORE

2015/02/16MEDICAL UPDATE

Asthma Society of Ireland – 23 February – Launch Event

We’re launching our new five year strategy and some important new research into what it means to have asthma and we want you to be there.

READ MORE

2015/01/13MEDICAL UPDATE

HMRC benchmarking for Pharmacists

Benchmarking is a guide devised by HM Revenue & Customs (HMRC) so that you can compare your business performance with other businesses in the same trade sector.

READ MORE

2014/11/25MEDICAL UPDATE

Mundipharma receives positive CHMP opinion for oxycodone / naloxone combination for the treatment of restless legs syndrome1

Dublin, 25 November 2014 – Mundipharma recently announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the fixed combination of prolonged-release oxycodone/naloxone, as a second line symptomatic treatment of patients with severe to very severe idiopathic restless legs syndrome (RLS), after failure of dopaminergic therapy.1

READ MORE

2014/10/28MEDICAL UPDATE

Mundipharma announces results of pivotal phase III study for fluticasone propionate/ formoterol pMDI in paediatric asthma

New data from a randomised, multicentre, phase III study, presented at the European Respiratory Society (ERS) annual congress in Munich, Germany, supports the potential of fluticasone propionate/ formoterol pMDIfor the treatment of paediatric asthma. The data presented shows the efficacy and tolerability of fluticasone propionate/ formoterol pMDI,over 12 weeks in children with asthma aged 5 to <12.

READ MORE

2014/10/10MEDICAL UPDATE

Confident but not controlled. (REALISE™)

92% of Irish people with asthma are confident about managing their condition however 48% are deemed ‘uncontrolled’1.  Pan-European Survey reveals low levels of asthma control in Ireland

READ MORE

2014/07/29MEDICAL UPDATE

Press Release: OZURDEX® Receives European positive opinion for the treatment of the sight threatening condition, Diabetic Macular Oedema (DME)

Sustained release treatment option could soon be available for diabetic patients in 28 countries of the European Union.  

READ MORE

2014/07/25MEDICAL UPDATE

Press Release: Is Europe putting cancer research at risk?

Lugano, Switzerland, 25 July 2014.  The European Society for Medical Oncology (ESMO), the leading pan-European association representing medical oncology professionals, has expressed concern that the proposed EU General Data Protection Regulation [1] could make cancer research impossible and add a significant burden to both doctors and cancer patients.

READ MORE

2014/07/24MEDICAL UPDATE

Press Release: Tough decision for Roche following mixed Phase II Trial results for Alzheimer’s drug

Roche faces difficult decision over entering Alzheimer’s disease (AD) drug crenezumab for Phase III clinical trials. ‘The company should be encouraged by the drug’s demonstrated efficacy in mild AD patients, as any agent with a modest effect in AD can potentially achieve blockbuster returns,’ says analyst. 

READ MORE